Association Between the Respiratory Microbiome and Susceptibility to Influenza Virus Infection.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
22 08 2020
Historique:
received: 07 06 2019
accepted: 26 09 2019
pubmed: 29 9 2019
medline: 28 4 2021
entrez: 29 9 2019
Statut: ppublish

Résumé

Previous studies suggest that the nose/throat microbiome may play an important role in shaping host immunity and modifying the risk of respiratory infection. Our aim is to quantify the association between the nose/throat microbiome and susceptibility to influenza virus infection. In this household transmission study, index cases with confirmed influenza virus infection and their household contacts were followed for 9-12 days to identify secondary influenza infections. Respiratory swabs were collected at enrollment to identify and quantify bacterial species via high-performance sequencing. Data were analyzed by an individual hazard-based transmission model that was adjusted for age, vaccination, and household size. We recruited 115 index cases with influenza A(H3N2) or B infection and 436 household contacts. We estimated that a 10-fold increase in the abundance in Streptococcus spp. and Prevotella salivae was associated with 48% (95% credible interval [CrI], 9-69%) and 25% (95% CrI, 0.5-42%) lower susceptibility to influenza A(H3N2) infection, respectively. In contrast, for influenza B infection, a 10-fold increase in the abundance in Streptococcus vestibularis and Prevotella spp. was associated with 63% (95% CrI, 17-83%) lower and 83% (95% CrI, 15-210%) higher susceptibility, respectively. Susceptibility to influenza infection is associated with the nose/throat microbiome at the time of exposure. The effects of oligotypes on susceptibility differ between influenza A(H3N2) and B viruses. Our results suggest that microbiome may be a useful predictor of susceptibility, with the implication that microbiome could be modulated to reduce influenza infection risk, should these associations be causal.

Sections du résumé

BACKGROUND
Previous studies suggest that the nose/throat microbiome may play an important role in shaping host immunity and modifying the risk of respiratory infection. Our aim is to quantify the association between the nose/throat microbiome and susceptibility to influenza virus infection.
METHODS
In this household transmission study, index cases with confirmed influenza virus infection and their household contacts were followed for 9-12 days to identify secondary influenza infections. Respiratory swabs were collected at enrollment to identify and quantify bacterial species via high-performance sequencing. Data were analyzed by an individual hazard-based transmission model that was adjusted for age, vaccination, and household size.
RESULTS
We recruited 115 index cases with influenza A(H3N2) or B infection and 436 household contacts. We estimated that a 10-fold increase in the abundance in Streptococcus spp. and Prevotella salivae was associated with 48% (95% credible interval [CrI], 9-69%) and 25% (95% CrI, 0.5-42%) lower susceptibility to influenza A(H3N2) infection, respectively. In contrast, for influenza B infection, a 10-fold increase in the abundance in Streptococcus vestibularis and Prevotella spp. was associated with 63% (95% CrI, 17-83%) lower and 83% (95% CrI, 15-210%) higher susceptibility, respectively.
CONCLUSIONS
Susceptibility to influenza infection is associated with the nose/throat microbiome at the time of exposure. The effects of oligotypes on susceptibility differ between influenza A(H3N2) and B viruses. Our results suggest that microbiome may be a useful predictor of susceptibility, with the implication that microbiome could be modulated to reduce influenza infection risk, should these associations be causal.

Identifiants

pubmed: 31562814
pii: 5575907
doi: 10.1093/cid/ciz968
pmc: PMC7442850
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

1195-1203

Subventions

Organisme : NIAID NIH HHS
ID : R01 AI120997
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI088654
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI119463
Pays : United States
Organisme : NIAID NIH HHS
ID : HHSN272201400006C
Pays : United States
Organisme : NIGMS NIH HHS
ID : U54 GM111274
Pays : United States

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Appl Environ Microbiol. 2013 Sep;79(17):5112-20
pubmed: 23793624
Nature. 2018 Jan 11;553(7687):238
pubmed: 29186118
Lancet. 2018 Mar 31;391(10127):1285-1300
pubmed: 29248255
Proc Natl Acad Sci U S A. 2011 Mar 29;108(13):5354-9
pubmed: 21402903
N Engl J Med. 2009 Dec 31;361(27):2619-27
pubmed: 20042753
Future Microbiol. 2012 May;7(5):609-24
pubmed: 22568716
PLoS Comput Biol. 2010 Jan 29;6(1):e1000656
pubmed: 20126529
Am J Epidemiol. 2013 Jun 15;177(12):1443-51
pubmed: 23629874
Am J Epidemiol. 2015 Oct 15;182(8):705-13
pubmed: 26400854
J Clin Microbiol. 2003 Aug;41(8):3487-93
pubmed: 12904343
J Gen Virol. 2017 Oct;98(10):2425-2437
pubmed: 28884664
PLoS One. 2016 Sep 19;11(9):e0162803
pubmed: 27643883
Epidemiol Rev. 1994;16(2):351-73
pubmed: 7713184
Emerg Infect Dis. 2018 Oct;24(10):1882-1888
pubmed: 30226161
PLoS One. 2013;8(1):e54574
pubmed: 23365674
Lancet Infect Dis. 2016 Aug;16(8):942-51
pubmed: 27061888
PLoS One. 2013 Sep 25;8(9):e75339
pubmed: 24086511
PLoS Pathog. 2014 Aug 21;10(8):e1004310
pubmed: 25144780
J Allergy Clin Immunol. 2014 Feb;133(2):405-13
pubmed: 24131826
Clin Infect Dis. 2018 Jul 18;67(3):327-333
pubmed: 29471464
PLoS One. 2012;7(2):e30126
pubmed: 22319561
PLoS One. 2019 Jan 9;14(1):e0207898
pubmed: 30625134
J Thorac Dis. 2013 Aug;5 Suppl 2:S127-31
pubmed: 23977433
Curr Opin Microbiol. 2017 Feb;35:8-15
pubmed: 27883933
Immunity. 2012 Jul 27;37(1):158-70
pubmed: 22705104
Ann Epidemiol. 2019 Sep;37:51-56.e6
pubmed: 31451313
Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):12578-12583
pubmed: 29109276
J Mol Evol. 2008 Jun;66(6):655-63
pubmed: 18504518
Trends Microbiol. 2016 Feb;24(2):123-133
pubmed: 26612500
J Infect Dis. 2014 Sep 1;210(5):684-92
pubmed: 24676208
FASEB J. 2010 Jun;24(6):1789-98
pubmed: 20097876
Nat Commun. 2019 Jan 10;10(1):106
pubmed: 30631062
J Mol Biol. 1990 Oct 5;215(3):403-10
pubmed: 2231712
PLoS Med. 2008 Mar 25;5(3):e74
pubmed: 18366252
Database (Oxford). 2010 Jul 06;2010:baq013
pubmed: 20624719
J Infect Dis. 2002 Aug 1;186(3):341-50
pubmed: 12134230

Auteurs

Tim K Tsang (TK)

Department of Biostatistics, University of Florida, Gainesville, Florida, USA.

Kyu Han Lee (KH)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.

Betsy Foxman (B)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.

Angel Balmaseda (A)

Sustainable Sciences Institute, Managua, Nicaragua.
Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

Lionel Gresh (L)

Sustainable Sciences Institute, Managua, Nicaragua.

Nery Sanchez (N)

Sustainable Sciences Institute, Managua, Nicaragua.

Sergio Ojeda (S)

Sustainable Sciences Institute, Managua, Nicaragua.

Roger Lopez (R)

Sustainable Sciences Institute, Managua, Nicaragua.
Laboratorio Nacional de Virología, Centro Nacional de Diagnóstico y Referencia, Ministry of Health, Managua, Nicaragua.

Yang Yang (Y)

Department of Biostatistics, University of Florida, Gainesville, Florida, USA.
Emerging Pathogens Institute, University of Florida, Gainesville, Florida, USA.

Guillermina Kuan (G)

Centro de Salud Sócrates Flores Vivas, Ministry of Health, Managua, Nicaragua.

Aubree Gordon (A)

Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH